HeyJaredJoyani Das
- Indexed articles, last 90 days
- 6
- Latest publication
- Sep 22, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 27, 2026
Latest articles
Six Cancer Therapies Move Toward Broader EU Use (opens the original)
Read excerpt
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended indication extensions for six already authorized oncology and hematology medicines at its September 2026 meeting. Abiraterone Mylan (abiraterone acetate; Mylan Pharmaceuticals Limited), Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca), Keytruda (pembrolizumab; Merck Sharp & Dohme), Padcev (enfortumab vedotin; Astellas Pharma), Pepaxti (melphalan flufenamide; Oncopeptides AB), and Tecvayl
EU Backs Three New Pediatric Growth Hormone Uses (opens the original)
Read excerpt
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended three new pediatric indications for Sogroya (somapacitan; Novo Nordisk), covering idiopathic short stature (ISS), short children born small for gestational age who have failed to show catch-up growth, and Noonan syndrome. If approved by the European Commission, Sogroya would become the first and only growth hormone therapy authorized for ISS in the EU. ISS is diagnosed in children who are marked
Three Cancer Drugs Advance Toward Broader EU Use (opens the original)
Read excerpt
Three established cancer therapies — Enhertu (trastuzumab deruxtecan, Daiichi Sankyo Europe), Piqray (alpelisib, Novartis Europharm), and Trodelvy (sacituzumab govitecan, Gilead Sciences) — moved closer to expanded use in the EU after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended extensions of indication for all three at its July 2026 meeting. The changes would move these agents earlier in treatment, introduce new combinations, or broaden acces
First Oral IL-23 Blocker Gets EMA Nod for Plaque Psoriasis (opens the original)
Read excerpt
People with moderate-to-severe plaque psoriasis in Europe could soon gain access to the first oral medicine targeting the interleukin (IL)-23 pathway, after the European Medicines Agency’s (EMA's) Committee for Medicinal Products for Human Use backed Icotyde (icotrokinra; Janssen-Cilag International). The recommendation covers adults and adolescents aged 12 years or older who weigh at least 40 kg and are candidates for systemic therapy. If approved by the European Commission, Icotyde would offer
New Cholesterol Drugs Move Closer to EU Approval (opens the original)
Read excerpt
European regulators have backed three new cholesterol-lowering therapies, potentially widening treatment options for patients who remain above low-density lipoprotein cholesterol (LDL-C) goals despite current therapy or cannot take statins. The Committee for Medicinal Products for Human Use (CHMP) recommended approval of Lyrokaul (lerodalcibep, LIB Therapeutics), Ubeslo (obicetrapib, A. Menarini International Licensing), and Evlarco (obicetrapib/ezetimibe, A. Menarini International Licensing). A
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.